Developer docs
API playgroundTry for free, no card

Search company profiles

Ribbon Biolabs

Full company profile

uuid0000yo5

Namestring
Ribbon Biolabs
Legal namestring
Ribbon Biolabs
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Ribbon Biolabs is a Vienna, Austria-based synthetic biology company founded in 2018 that operates a proprietary cell-free DNA synthesis platform designed to bypass traditional bacterial cloning workflows. The company's core commercial product, MiroSynth™ Cell-Free DNA, is built without bacteria and is positioned to eliminate bacterial contaminants, residual host DNA, cloning-based delays, and design compromises caused by toxicity or instability in bacterial systems. A second product, MiroMine™, is a kit-based cell-free DNA synthesis offering currently in beta that enables on-site construction of complex DNA without cloning.

The company targets research and development teams across mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing. It cites industry pain points including sequences that traditional providers cannot manufacture (claimed to affect 84% of teams) and rejections driven by complexity or length limits (50% of rejections), and notes that 75% of teams in mRNA, CAR-T, and vaccines prefer cell-free DNA. Its go-to-market is product-led, with MiroSynth sold via direct enterprise engagement initiated through the website and MiroMine accessed through a beta application.

Ribbon Biolabs is a privately held company with 51-100 employees, based in Vienna. It has raised approximately $20.2 million in disclosed institutional funding, led by Hadean Ventures with participation from Helicase Venture, Lansdowne Partners, tecnet equity, and XISTA Science Ventures. The leadership team includes CEO Jodi Barrientos, founders Wladimir Labeikovsky and Harold P. de Vladar, Executive Chairman Roopom Banerjee, Chair Dr. Urs Spitz, and Vice President, Global Head of Sales Jeff Fitzgerald. Pricing is not publicly disclosed, and no customer logos are listed in available sources.

Short descriptiontext

Ribbon Biolabs is a Vienna-based synthetic biology company that provides cell-free synthetic DNA products (MiroSynth™ and MiroMine™) to R&D teams in mRNA therapies, vaccines, cell and gene therapies, protein engineering, and gene editing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cell-free DNA synthesis, synthetic biology products, DNA manufacturing services, gene synthesis platform, molecular biology tools
Industry3 codes
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Synthetic DNA / Synthetic Biology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1MiroSynth™ Cell-Free DNA Products
TypeOne Time License
Description

Sale of cell-free synthetic DNA products for research and development applications in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.

ribbonbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MiroSynth™ Cell-Free DNA
Description

Cell-free synthetic DNA product enabling faster progression into downstream applications with greater confidence, built without bacteria.

ribbonbio.com
+1 more record
Core offering1 text field

Ribbon Biolabs manufactures and supplies cell-free synthetic DNA products for biotechnology research and therapeutic development. Its core commercial product, MiroSynth™ Cell-Free DNA, delivers complex synthetic DNA sequences manufactured without bacterial cloning workflows, eliminating bacterial contaminants, residual host DNA, cloning delays, and design compromises from toxicity or instability. The company also offers MiroMine™, a kit-based in-lab cell-free DNA production system (currently in beta) that lets research teams build complex DNA on-site.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Eliminates bacterial contaminants and residual host DNA from synthetic DNA products
+2 more records
Product overview1 text field

Ribbon Biolabs offers a portfolio of cell-free synthetic DNA products centered around MiroSynth™ Cell-Free DNA and MiroMine™. MiroSynth™ is the core commercial product enabling complex DNA synthesis without bacterial workflows, while MiroMine™ is a kit-based solution in beta that allows in-lab cell-free DNA production. The company focuses on eliminating limitations of traditional bacterial-based DNA synthesis for applications in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.

Product and service2 records
1MiroSynth™ Cell-Free DNA
CategorySynthetic DNA Products
Description

Cell-free synthetic DNA product built without bacteria, enabling faster progression into downstream applications with greater confidence. Eliminates bacterial contaminants, residual host DNA, delays from cloning-based workflows, and design compromises from toxicity or instability. Designed for research teams in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.

2MiroMine™
CategorySynthetic DNA Kits
Description

Kit-based, cell-free DNA production kit currently in beta that allows research teams to build complex DNA on-site without cloning or delays. Part of the MiroMine™ beta program for accessible kit-based, cell-free DNA synthesis.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript provides gene synthesis, plasmid manufacturing, and protein services to mRNA, cell therapy, and gene therapy developers. It is a direct competitor to Ribbon Bio's MiroSynth offering in therapeutic-grade DNA templates.

TypeDirect peer
Description

Twist Bioscience is a leading DNA synthesis provider offering both synthetic genes and an oligo pool platform via silicon-based synthesis. It directly competes with Ribbon Bio in selling synthetic DNA to mRNA, vaccine, and gene therapy R&D teams, though at much larger scale.

3DNA Script
TypeEmerging player
Description

DNA Script develops enzymatic (cell-free) DNA synthesis platforms and benchtop printers, overlapping with Ribbon Bio's MiroMine™ kit vision. Both target the same shift away from bacterial/clonal workflows.

TypeDirect peer
Description

IDT is one of the largest custom synthetic DNA/oligo providers serving academic, pharma, and gene synthesis customers globally. It overlaps directly with Ribbon Bio on gene synthesis for mRNA, gene editing, and synthetic biology workflows.

TypeEmerging player
Description

ATUM provides gene synthesis, protein engineering, and synthetic biology tools to therapeutics and industrial biotech customers. It is a comparable niche competitor in synthetic DNA and protein engineering applications.

TypeBroad incumbent
Description

NEB is a broad incumbent in molecular biology enzymes and reagents with adjacent offerings in DNA assembly and synthetic biology workflows. It is comparable as a foundational life-sciences tools supplier overlapping with Ribbon Bio's research customer base.

TypeDirect peer
Description

Eurofins Genomics is a major European synthetic DNA and genomics services provider. As a European-headquartered competitor, it overlaps with Ribbon Bio's region and customer segments, particularly in research-grade gene synthesis.

TypeEmerging player
Description

Camena Bioscience is an emerging synthetic biology company building enzymatic DNA synthesis technology. It competes with Ribbon Bio in the cell-free, high-fidelity synthetic DNA space serving therapeutics and synthetic biology customers.

TypeDirect peer
Description

Synbio Technologies provides gene synthesis, plasmid construction, and synthetic biology services. It competes with Ribbon Bio for gene synthesis orders from mRNA, gene therapy, and academic customers, particularly in Asia.

TypeEmerging player
Description

Ansa Biotechnologies is developing a novel enzymatic DNA synthesis approach for long, complex DNA sequences. It competes directly with Ribbon Bio's core value proposition of synthesizing complex constructs cell-free.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ribbon Biolabs

Synthetic DNA / Synthetic Biologyribbonbiolabs.com

Ribbon Biolabs is a Vienna-based synthetic biology company that provides cell-free synthetic DNA products (MiroSynth™ and MiroMine™) to R&D teams in mRNA therapies, vaccines, cell and gene therapies, protein engineering, and gene editing.

What Ribbon Biolabs does

Ribbon Biolabs is a Vienna, Austria-based synthetic biology company founded in 2018 that operates a proprietary cell-free DNA synthesis platform designed to bypass traditional bacterial cloning workflows. The company's core commercial product, MiroSynth™ Cell-Free DNA, is built without bacteria and is positioned to eliminate bacterial contaminants, residual host DNA, cloning-based delays, and design compromises caused by toxicity or instability in bacterial systems. A second product, MiroMine™, is a kit-based cell-free DNA synthesis offering currently in beta that enables on-site construction of complex DNA without cloning.

The company targets research and development teams across mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing. It cites industry pain points including sequences that traditional providers cannot manufacture (claimed to affect 84% of teams) and rejections driven by complexity or length limits (50% of rejections), and notes that 75% of teams in mRNA, CAR-T, and vaccines prefer cell-free DNA. Its go-to-market is product-led, with MiroSynth sold via direct enterprise engagement initiated through the website and MiroMine accessed through a beta application.

Ribbon Biolabs is a privately held company with 51-100 employees, based in Vienna. It has raised approximately $20.2 million in disclosed institutional funding, led by Hadean Ventures with participation from Helicase Venture, Lansdowne Partners, tecnet equity, and XISTA Science Ventures. The leadership team includes CEO Jodi Barrientos, founders Wladimir Labeikovsky and Harold P. de Vladar, Executive Chairman Roopom Banerjee, Chair Dr. Urs Spitz, and Vice President, Global Head of Sales Jeff Fitzgerald. Pricing is not publicly disclosed, and no customer logos are listed in available sources.

Ribbon Biolabs firmographics

Firmographics
Name
Ribbon Biolabs
Legal name
Ribbon Biolabs
Website
https://ribbonbiolabs.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Ribbon Biolabs is a Vienna-based synthetic biology company that provides cell-free synthetic DNA products (MiroSynth™ and MiroMine™) to R&D teams in mRNA therapies, vaccines, cell and gene therapies, protein engineering, and gene editing.
Ownership category
akta.pro rank

Ribbon Biolabs industry classification

Industry
Product category
Synthetic DNA / Synthetic Biology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services

Keywords

  • Cell-free DNA synthesis
  • Synthetic biology products
  • DNA manufacturing services
  • Gene synthesis platform
  • Molecular biology tools

Where Ribbon Biolabs is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Markets served

Ribbon Biolabs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. MiroSynth™ Cell-Free DNA Products: Sale of cell-free synthetic DNA products for research and development applications in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ribbon Biolabs product offering

Product offering

Core offering

Ribbon Biolabs manufactures and supplies cell-free synthetic DNA products for biotechnology research and therapeutic development. Its core commercial product, MiroSynth™ Cell-Free DNA, delivers complex synthetic DNA sequences manufactured without bacterial cloning workflows, eliminating bacterial contaminants, residual host DNA, cloning delays, and design compromises from toxicity or instability. The company also offers MiroMine™, a kit-based in-lab cell-free DNA production system (currently in beta) that lets research teams build complex DNA on-site.

Product overview

Ribbon Biolabs offers a portfolio of cell-free synthetic DNA products centered around MiroSynth™ Cell-Free DNA and MiroMine™. MiroSynth™ is the core commercial product enabling complex DNA synthesis without bacterial workflows, while MiroMine™ is a kit-based solution in beta that allows in-lab cell-free DNA production. The company focuses on eliminating limitations of traditional bacterial-based DNA synthesis for applications in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.

Differentiator

Problem solved

Functional benefit

Brands

  • MiroSynth™ Cell-Free DNA: Cell-free synthetic DNA product enabling faster progression into downstream applications with greater confidence, built without bacteria.
  • MiroMine™

Products and services

  • MiroSynth™ Cell-Free DNA Cell-free synthetic DNA product built without bacteria, enabling faster progression into downstream applications with greater confidence. Eliminates bacterial contaminants, residual host DNA, delays from cloning-based workflows, and design compromises from toxicity or instability. Designed for research teams in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.
  • MiroMine™ Kit-based, cell-free DNA production kit currently in beta that allows research teams to build complex DNA on-site without cloning or delays. Part of the MiroMine™ beta program for accessible kit-based, cell-free DNA synthesis.

Quantifiable outcome

  • Eliminates bacterial contaminants and residual host DNA from synthetic DNA products
  • +2 more outcomes

Companies that use Ribbon Biolabs

Customer profile

Segments5 records

Ideal customer profiles1 record

Ribbon Biolabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ribbon Biolabs partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Ribbon Biolabs competitors and assessment

Company assessment

Direct peers

  • GenScript: GenScript provides gene synthesis, plasmid manufacturing, and protein services to mRNA, cell therapy, and gene therapy developers. It is a direct competitor to Ribbon Bio's MiroSynth offering in therapeutic-grade DNA templates.
  • Twist Bioscience: Twist Bioscience is a leading DNA synthesis provider offering both synthetic genes and an oligo pool platform via silicon-based synthesis. It directly competes with Ribbon Bio in selling synthetic DNA to mRNA, vaccine, and gene therapy R&D teams, though at much larger scale.
  • Integrated DNA Technologies (IDT): IDT is one of the largest custom synthetic DNA/oligo providers serving academic, pharma, and gene synthesis customers globally. It overlaps directly with Ribbon Bio on gene synthesis for mRNA, gene editing, and synthetic biology workflows.
  • Eurofins Genomics: Eurofins Genomics is a major European synthetic DNA and genomics services provider. As a European-headquartered competitor, it overlaps with Ribbon Bio's region and customer segments, particularly in research-grade gene synthesis.
  • Synbio Technologies: Synbio Technologies provides gene synthesis, plasmid construction, and synthetic biology services. It competes with Ribbon Bio for gene synthesis orders from mRNA, gene therapy, and academic customers, particularly in Asia.

Emerging players

  • DNA Script: DNA Script develops enzymatic (cell-free) DNA synthesis platforms and benchtop printers, overlapping with Ribbon Bio's MiroMine™ kit vision. Both target the same shift away from bacterial/clonal workflows.
  • ATUM (formerly DNA2.0): ATUM provides gene synthesis, protein engineering, and synthetic biology tools to therapeutics and industrial biotech customers. It is a comparable niche competitor in synthetic DNA and protein engineering applications.
  • Camena Bioscience: Camena Bioscience is an emerging synthetic biology company building enzymatic DNA synthesis technology. It competes with Ribbon Bio in the cell-free, high-fidelity synthetic DNA space serving therapeutics and synthetic biology customers.
  • Ansa Biotechnologies: Ansa Biotechnologies is developing a novel enzymatic DNA synthesis approach for long, complex DNA sequences. It competes directly with Ribbon Bio's core value proposition of synthesizing complex constructs cell-free.

Broad incumbents

  • New England Biolabs (NEB): NEB is a broad incumbent in molecular biology enzymes and reagents with adjacent offerings in DNA assembly and synthetic biology workflows. It is comparable as a foundational life-sciences tools supplier overlapping with Ribbon Bio's research customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Ribbon Biolabs social profiles

Digital presence

Ribbon Biolabs compliance and trust

Trust signal

Compliance1 record

Ribbon Biolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ribbon Biolabs leadership team

Management profile

Number of profiles

Profiles6 records

Ribbon Biolabs funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ribbon Biolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ribbon Biolabs

What does Ribbon Biolabs do?

Ribbon Biolabs manufactures and supplies cell-free synthetic DNA products for biotechnology research and therapeutic development. Its core commercial product, MiroSynth™ Cell-Free DNA, delivers complex synthetic DNA sequences manufactured without bacterial cloning workflows, eliminating bacterial contaminants, residual host DNA, cloning delays, and design compromises from toxicity or instability. The company also offers MiroMine™, a kit-based in-lab cell-free DNA production system (currently in beta) that lets research teams build complex DNA on-site.

Is Ribbon Biolabs a public or private company?

Ribbon Biolabs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ribbon Biolabs founded?

Ribbon Biolabs was founded in 2018. It employs 51 to 100 people.

Where is Ribbon Biolabs based?

Ribbon Biolabs is headquartered in Vienna, Austria, in the Europe region.

How does Ribbon Biolabs make money?

One revenue line is on record: miroSynth™ Cell-Free DNA Products.

Who are Ribbon Biolabs's main competitors?

Direct peers on record are GenScript, Twist Bioscience, Integrated DNA Technologies (IDT), Eurofins Genomics and Synbio Technologies. Emerging players are DNA Script, ATUM (formerly DNA2.0), Camena Bioscience and Ansa Biotechnologies. New England Biolabs (NEB) is listed as a broad incumbent.

Does Ribbon Biolabs have an API?

No public API is recorded for Ribbon Biolabs.

What industry is Ribbon Biolabs in?

Ribbon Biolabs's product category is Synthetic DNA / Synthetic Biology. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRibbon Bio Launches Cell-Free MiroSynth DNA and New In-Lab Cell-Free DNA Production KitRibbon Bio launched MiroSynth cell-free DNA and the MiroMine kit for in-lab DNA production. The cell-free approach removes bacterial cloning steps, improving purity and scalability. The MiroMine kit is available via beta testing.Business Wire BlogRibbon Biolabs Appoints Roopom Banerjee as Executive ChairmanRibbon Biolabs appointed Roopom Banerjee as Executive Chairman, bringing 25 years of life science experience. He previously led RainDance Technologies and now serves as Managing Partner at WhiteLeaf Advisors. The company aims to industrialize synthetic DNA manufacturing for biomedical applications.BioSpaceRibbon Biolabs Appoints Jodi Barrientos as Chief Business OfficerRibbon Biolabs appointed Jodi Barrientos as Chief Business Officer, bringing over 17 years of experience in life science and diagnostics. She will lead commercial efforts for DNA synthesis, including the Early Access program, and previously served as VP of Commercial Marketing at Agilent Technologies.BioSpaceRibbon Biolabs Reaches Key Milestone with Automation of InfiniSynthTM Platform for Commercial-scale, Unlimited Length DNA SynthesisRibbon Biolabs announced the successful implementation of its InfiniSynth platform for automated assembly of long DNA, achieved with HighRes Biosolutions. The platform enables production of DNA molecules over 10,000 base pairs in length, supporting commercial-scale synthetic DNA for biopharmaceutical research.Business Wire BlogRibbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis TechnologyRibbon Biolabs received U.S. Patent US 2020283756 A1 for its long DNA synthesis method, the first granted patent in its portfolio. The method uses a pre-built oligonucleotide library to synthesize DNA up to 20,000 base pairs, including a recent 20,000 bp molecule for an undisclosed pharma client.BioSpaceRibbon Biolabs Raises EUR 18 Million Series A Financing Enabling Commercial Scale Production Facilities and US Expansion for DNA Synthesis TechnologyRibbon Biolabs announced the successful close of an EUR 18 million Series A funding round led by Hadean Ventures with participation from Lansdowne Partners, Helicase Venture, and existing investors. The capital will be utilized to establish commercial-scale production facilities for its DNA synthesis technology and to facilitate expansion into the US market. This investment supports the company's strategic growth in synthetic biology, building on recent validations of its proprietary enzymatic assembly capabilities.FinSMEsRibbon Biolabs Raises EUR18M in Series A FinancingRibbon Biolabs, a Vienna-based DNA synthesis company, closed an EUR 18 million Series A funding round led by Hadean Ventures. The company plans to utilize the capital for commercializing its automated enzymatic DNA assembly technology and expanding into the US market.